Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARCᅢᄁ¬ダᅡᄁ) platform to develop a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and inflammatory diseases. Using its ARCᅢᄁ¬ダᅡᄁ platform, Shattuck is building a pipeline of therapeutics, that consolidate checkpoint blockade and TNF receptor agonists into single therapeutics to improve outcomes for patients. Shattuck has offices in Austin, Texas and Durham, North Carolina.